Mohammad Omar Hussaini1, Abu-Sayeef Mirza2, Rami Komrokji3, Jeffrey Lancet3, Eric Padron3, Jinming Song1. 1. Department of Hematopathology, Moffitt Cancer Center, Tampa, FL, U.S.A. 2. Department of Internal Medicine, University of South Florida, Tampa, FL, U.S.A mirzaa@mail.usf.edu. 3. Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, U.S.A.
Abstract
BACKGROUND/AIM: Acute myeloid leukemia (AML) represents a heterogeneous disease with varying morphologic, immunophenotypic, and genetic features, along with varying patient outcomes. The genomic tractability of AML makes it amenable for targeted next-generation sequencing (NGS) testing clinically. MATERIALS AND METHODS: One hundred eights-seven unique patients with a diagnosis of acute myeloid leukemia between May 2011 and Oct 2014 and with mutational analysis by NGS were included in this study. The distribution of gene mutations was investigated in different subcategories of AML. RESULTS: Most patients in this study (n=182) received Genoptix testing (either 5-gene panel or 21-gene panel). In 130/187 (70%) cases, there was an average of 2.3 mutations per case (range=0-7 mutations). We specifically mention mutations in 32 genes, their significance and co-occurrence as detected in different types of AML. CONCLUSION: The genetic heterogeneity of AML signifies the importance of taking a personalized-medicine approach to the management of patients with AML. Copyright
BACKGROUND/AIM: Acute myeloid leukemia (AML) represents a heterogeneous disease with varying morphologic, immunophenotypic, and genetic features, along with varying patient outcomes. The genomic tractability of AML makes it amenable for targeted next-generation sequencing (NGS) testing clinically. MATERIALS AND METHODS: One hundred eights-seven unique patients with a diagnosis of acute myeloid leukemia between May 2011 and Oct 2014 and with mutational analysis by NGS were included in this study. The distribution of gene mutations was investigated in different subcategories of AML. RESULTS: Most patients in this study (n=182) received Genoptix testing (either 5-gene panel or 21-gene panel). In 130/187 (70%) cases, there was an average of 2.3 mutations per case (range=0-7 mutations). We specifically mention mutations in 32 genes, their significance and co-occurrence as detected in different types of AML. CONCLUSION: The genetic heterogeneity of AML signifies the importance of taking a personalized-medicine approach to the management of patients with AML. Copyright
Authors: Lisa Pieri; Ambra Spolverini; Barbara Scappini; Umberto Occhini; Silvia Birtolo; Alberto Bosi; Francesco Albano; Carmen Fava; Alessandro M Vannucchi Journal: Blood Date: 2011-09-22 Impact factor: 22.113
Authors: Marta Pratcorona; Saman Abbas; Mathijs A Sanders; Jasper E Koenders; François G Kavelaars; Claudia A J Erpelinck-Verschueren; Annelieke Zeilemakers; Bob Löwenberg; Peter J M Valk Journal: Haematologica Date: 2011-11-04 Impact factor: 9.941
Authors: S Schnittger; C Eder; S Jeromin; T Alpermann; A Fasan; V Grossmann; A Kohlmann; T Illig; N Klopp; H-E Wichmann; K-A Kreuzer; C Schmid; P Staib; R Peceny; N Schmitz; W Kern; C Haferlach; T Haferlach Journal: Leukemia Date: 2012-09-11 Impact factor: 11.528
Authors: D Grimwade; H Walker; F Oliver; K Wheatley; C Harrison; G Harrison; J Rees; I Hann; R Stevens; A Burnett; A Goldstone Journal: Blood Date: 1998-10-01 Impact factor: 22.113
Authors: Sylvain Mareschal; Anna Palau; Johan Lindberg; Philippe Ruminy; Christer Nilsson; Sofia Bengtzén; Marie Engvall; Anna Eriksson; Anne Neddermeyer; Vinciane Marchand; Monika Jansson; My Björklund; Fabrice Jardin; Mattias Rantalainen; Andreas Lennartsson; Lucia Cavelier; Henrik Grönberg; Sören Lehmann Journal: Blood Adv Date: 2021-02-23
Authors: Jayakumar Vadakekolathu; Catherine Lai; Stephen Reeder; Sarah E Church; Tressa Hood; Anbarasu Lourdusamy; Michael P Rettig; Ibrahim Aldoss; Anjali S Advani; John Godwin; Matthew J Wieduwilt; Martha Arellano; John Muth; Tung On Yau; Farhad Ravandi; Kendra Sweet; Heidi Altmann; Gemma A Foulds; Friedrich Stölzel; Jan Moritz Middeke; Marilena Ciciarello; Antonio Curti; Peter J M Valk; Bob Löwenberg; Ivana Gojo; Martin Bornhäuser; John F DiPersio; Jan K Davidson-Moncada; Sergio Rutella Journal: Blood Adv Date: 2020-10-27
Authors: Doris K Hansen; Jongphil Kim; Zachary Thompson; Mohammad Hussaini; Taiga Nishihori; Anam Ahmad; Hany Elmariah; Rawan Faramand; Asmita Mishra; Marco L Davila; Farhad Khimani; Aleksandr Lazaryan; David Sallman; Hien Liu; Lia E Perez; Hugo Fernandez; Michael L Nieder; Jeffrey E Lancet; Joseph A Pidala; Claudio Anasetti; Nelli Bejanyan Journal: Transplant Cell Ther Date: 2021-02-02